Mechanistic Rationale of Seladelpar’s Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis
Abstract
Seladelpar is a selective PPAR-δ agonist approved for the treatment of the rare cholestatic disease Primary Biliary Cholangitis, in patients who do not achieve adequate biochemical control with first-line therapy. This review outlines the characteristics of PPAR-δ, with insights into its activity across different tissues, and summarizes the pharmacology of Seladelpar, providing the background for the subsequent discussion of its clinical efficacy and safety in humans.
Fields of Study & Subjects
Liver Diseases and Immunity
Drug Transport and Resistance Mechanisms
Pediatric Hepatobiliary Diseases and Treatments
Publication details
- Journal / source
- Pharmacological Research
- Publisher
- Elsevier BV
- Volume
- 225
- Pages
- 108144–108144
- Publication date
- 17 February 2026
- Language
- EN